GlobeNewswire·Jun 11, 2026, 7:00 AM ET

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease

AC Immune SA will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of the Phase 2 VacSYn trial for ACI-7104 in early Parkinson's disease.
The extension aims to assess the long-term safety & efficacy of the anti-alpha-synuclein active immunotherapy for an additional 2 years.
Final data from Part 1 of the VacSYn trial is expected in the second half of 2026.
The long-term dataset is intended to benefit individuals with prodromal & early PD who require prolonged treatment & a well-established safety profile.
Interim results reported in December 2025 indicated a disease-modifying effect, favorable safety profile, robust antibody responses, & evidence of target engagement.
ACI-7104.056 is an optimized formulation designed to inhibit the spreading of pathological oligomeric alpha-synuclein & downstream neurodegeneration.
AC Immune SA is a clinical-stage biopharmaceutical company focused on precision prevention for neurodegenerative diseases using its SupraAntigen® & Morphomer® technology platforms.